Antiplatelet therapy: New score for predicting bleeding risk after DAPT

Nat Rev Cardiol. 2017 May 15;14(6):321-322. doi: 10.1038/nrcardio.2017.71.

Authors

Bastiaan Zwart¹, Jurriën M Ten Berg¹

Affiliation

¹ Department of Cardiology, St. Antonius Hospital, Koekoekslaan 1, Nieuwegein, The Netherlands.

PMID: 28504270
DOI: 10.1038/nrcardio.2017.71

No abstract available

MeSH terms

Aspirin / pharmacology*
Clinical Trials as Topic
Coronary Restenosis / prevention & control*
Hemorrhage* / chemically induced
Hemorrhage* / diagnosis
Humans
Long Term Adverse Effects* / chemically induced
Long Term Adverse Effects* / diagnosis
Outpatients
Percutaneous Coronary Intervention / adverse effects
Percutaneous Coronary Intervention / instrumentation
Platelet Aggregation Inhibitors / pharmacology
Predictive Value of Tests
Prognosis
Purinergic P2Y Receptor Antagonists / pharmacology*
Reproducibility of Results
Research Design
Risk Adjustment / methods
Stents / adverse effects

Substances

Platelet Aggregation Inhibitors
Purinergic P2Y Receptor Antagonists
Aspirin